- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06395246
Circulating Microvesicles Regulating Metabolic Homeostasis in Obesity After Caloric Restriction Programs (TREV)
The Usefulness of Circulating Microvesicles (host and Bacterial) in Regulating Metabolic Homeostasis in Obesity Randomized Study of Parallel Arms in Obese Patients Undergoing Caloric Restriction Diet Vs. Early Time-restricted Eating
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The specific objectives are:
- To assess the effect of two dietary protocols on weight loss and metabolic benefits in non-morbidly obese subjects.
- Influence of both protocols on energy signaling metabolites and the dynamics of enteroendocrine hormones.
- Define the "digital footprint" of EVs as inter-organ communication elements influencing metabolic status in obese subjects.
The study design comprises a randomized parallel-arm design (n=40) with consecutive 1:1 allocation to a calorie restriction protocol for a healthy Mediterranean diet under Daily Caloric Restriction (DCR) (n=20) or an eTRE protocol (n=20) for 12 weeks. Clinical and analytical variables, adherence, satiety, chronotype, and brown fat content will be determined before and at the end of the follow-up. Derivatives of intestinal microbiota, short-chain fatty acids, bile acids, and circulating metabolites derived from host intermediary metabolism will be assessed through metabolomics. Glucagon-like peptide 1 (GLP1) and gastric inhibitory polypeptide (GIP) dynamics after a standard meal test. Metagenomics. Bioenergetic analysis of PBMC by SeaHorse. Total EV miRNA profile. Isolation of host and bacterial EVs. Characterization of the protein cargo of host and bacterial EVs.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Juan José Vendrell Ortega, Professor
- Phone Number: +34 619672912
- Email: jvortega2002@gmail.com
Study Locations
-
-
-
Tarragona, Spain, 43005
- Recruiting
- Hospital Universitario de Tarragona Juan XXIII
-
Contact:
- Juan Jose Vendrell Ortega, PhD, MD, Professor
- Phone Number: +34 977295800
- Email: jvortega2002@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- age between 18 and 70 years old.
- BMI ranges between 27 and 40 kg/ m2.
- Absence of underlying pathology in medical and physical examination, except for those related to excess weight.
- Signature of the informed consent for participation in the study.
Exclusion Criteria:
- Serious systemic disease not related to obesity, such as cancer, kidney or severe liver disease.
- Systemic diseases with intrinsic inflammatory activity (autoimmune diseases such as rheumatoid arthritis and asthma).
- Pregnancy and lactation.
- Vegetarians or subjects subjected to an irregular diet.
- Patients with severe eating disorders.
- Patients with clinical symptoms and signs of infection in the previous month.
- Patients with chronic anti-inflammatory steroid treatments and/or nonsteroidal anti-inflammatory drugs.
- Recent antibiotic treatment.
- Uncontrolled alcoholism or drug abuse.
- Rotating or nocturnal shift workers.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Continuous caloric restriction
Continuous calorie restriction diet based on healthy Mediterranean diet recommendations
|
Individualized continuous calorie restriction diet based on healthy Mediterranean diet recommendations aiming to achieve at least a 5% weight loss at the end of the intervention
|
|
Experimental: eTRE
early (morning) time-restricted eating (eTRE) plus continuous caloric restriction diet based on healthy Mediterranean diet recommendations
|
early (morning) time-restricted eating pluss individualized continuous calorie restriction diet based on healthy Mediterranean diet recommendations aiming to achieve at least a 5% weight loss at the end of the intervention
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Anthropometric measurements (I)
Time Frame: Before and after (12 weeks) of the intervention
|
Changes in weight (kg)
|
Before and after (12 weeks) of the intervention
|
|
Anthropometric measurements (II)
Time Frame: Before and after (12 weeks) of the intervention
|
Changes in body mass index (kg/m^2);
|
Before and after (12 weeks) of the intervention
|
|
Anthropometric measurements (III)
Time Frame: Before and after (12 weeks) of the intervention
|
Changes waist circumference (cm)
|
Before and after (12 weeks) of the intervention
|
|
Anthropometric measurements (IV)
Time Frame: Before and after (12 weeks) of the intervention
|
Changes hip circumference (cm)
|
Before and after (12 weeks) of the intervention
|
|
Anthropometric measurements (V)
Time Frame: Before and after (12 weeks) of the intervention
|
Changes neck circumference (cm)
|
Before and after (12 weeks) of the intervention
|
|
Body composition (I)
Time Frame: Before and after (12 weeks) of the intervention
|
Changes in fat body mass (kg); assesed by bioimpedance monitoring device (Seca®)
|
Before and after (12 weeks) of the intervention
|
|
Body composition (II)
Time Frame: Before and after (12 weeks) of the intervention
|
Changes in lean body mass (kg); assesed by bioimpedance monitoring device (Seca®)
|
Before and after (12 weeks) of the intervention
|
|
Body composition (III)
Time Frame: Before and after (12 weeks) of the intervention
|
Changes visceral adipose tissue (L); assesed by bioimpedance monitoring device (Seca®)
|
Before and after (12 weeks) of the intervention
|
|
Brown fat
Time Frame: Before and after (12 weeks) of the intervention
|
Changes in brown fat volume (cm3); assessed by magnetic resonance image (MRI)
|
Before and after (12 weeks) of the intervention
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Gut and host microbiota-derived metabolites (I)
Time Frame: Before and after (12 weeks) of the intervention
|
Changes in circulating short-chain fatty acids levels [µM]; assesed by Gas Chromatography-Tandem Mass Spectrometry (GC-MS/MS)
|
Before and after (12 weeks) of the intervention
|
|
Gut and host microbiota-derived metabolites (II)
Time Frame: Before and after (12 weeks) of the intervention
|
Changes in circulating bile acids levels [nM]; Liquid Chromatography-Tandem Mass Spectrometry (LC-MS/MS)
|
Before and after (12 weeks) of the intervention
|
|
Gut and host microbiota-derived metabolites (III)
Time Frame: Before and after (12 weeks) of the intervention
|
Changes in circulating succinate levels [µM]; assesed by EnzyChrom™ Succinate Assay Kit
|
Before and after (12 weeks) of the intervention
|
|
Entero-endocrine incretin hormones (I)
Time Frame: Before and after (12 weeks) of the intervention
|
Changes in post-prandial response to a meal-tolerance test in serum levels of glucose [mg/dL]; assesed by ELISA kit
|
Before and after (12 weeks) of the intervention
|
|
Entero-endocrine incretin hormones (II)
Time Frame: Before and after (12 weeks) of the intervention
|
Changes in post-prandial response to a meal-tolerance test in serum levels of insulin levels [pmol/L] ]assesed by ELISA kit
|
Before and after (12 weeks) of the intervention
|
|
Entero-endocrine incretin hormones (III)
Time Frame: Before and after (12 weeks) of the intervention
|
Changes in post-prandial response to a meal-tolerance test in plasma levels of glucagon-like peptite 1 [GLP-1 ] (pmol/L); assesed by ELISA kit
|
Before and after (12 weeks) of the intervention
|
|
Entero-endocrine incretin hormones (IV)
Time Frame: Before and after (12 weeks) of the intervention
|
Changes in post-prandial response to a meal-tolerance test in plasma levels of gastric inhibitory polypeptide (GIP) [pg/mL]; assesed by ELISA kit
|
Before and after (12 weeks) of the intervention
|
|
Microbial composition/metagenomic
Time Frame: Before and after (12 weeks) of the intervention
|
Changes in alpha and beta diversity, relative abundance and functional metagenomics; assesed by Ilumina metagenomics
|
Before and after (12 weeks) of the intervention
|
|
Cellular energy metabolism
Time Frame: Before and after (12 weeks) of the intervention
|
Changes in Cluster of Differentiation 14 positive (CD14+) monocytes isolated from peripheral blood mononuclear cells (PBMCs) will be used for bioenergetics analysis via an extracellular flux analyzer
|
Before and after (12 weeks) of the intervention
|
Collaborators and Investigators
Investigators
- Principal Investigator: Juan José Vendrell Ortega, Professor, Instituto de Investigación Sanitaria Pere Virgili (IISPV)
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PI23/01133
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.